Rejected: After paying $80M to acquire it, Mallinckrodt’s jaundice drug snubbed by FDA’s advisory committee

Mallinckrodt just got a big thumbs down from the FDA’s advisors who say data on the company’s newly-acquired jaundice drug isn’t convincing a majority of the group that it’s safe and effective.